Boston Scientific to Divest BTG’s Specialty Pharma Business for ~$800M

December 2, 2020 Auto Bot Agreement, Boston, Business, International, M&A, Pharmaceuticals, Signs 0

Shots:

  • Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in H1’21
  • The agreement includes the transfer of 5 facilities & ~280 employees globally. This transaction will help the BTG specialty pharma business enhance its potential as a fully integrated specialty pharmaceuticals platform
  • Boston Scientific acquired BTG for ~$3.7B in 2019. The divested products include life-saving antidotes used in hospitals & emergency care settings, including CroFab, DigiFab & Voraxaze

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Barron’s

The post Boston Scientific to Divest BTG’s Specialty Pharma Business for ~0M first appeared on PharmaShots.